Avacopan CAS: 1346623-17-3 is a new medication that is being researched for its therapeutic effects. This medication is a type of drug known as a C5a receptor inhibitor. It is currently in development for the treatment of various medical conditions such as vasculitis and other inflammatory disorders. This article will provide you with more information about avacopan.
The chemical name of avacopan is N-((S)-1-(4-(6-ethoxy-5-oxo-4,5-dihydropyrimidin-2-yl)phenyl)ethyl)-4-(naphthalene-1-ylmethyl)piperazine-1-carboxamide.
The molecular formula of avacopan is C33H37N5O3.
The formula weight of avacopan is 551.69 g/mol.
The CAS number for avacopan is 1346623-17-3.
Top ten keywords from Google and synonyms:
- Avacopan for vasculitis
- C5a receptor inhibitor
- Anti-inflammatory drug
- Complement system inhibitor
- Clinical trials for avacopan
- Potential benefits of avacopan
- Immune system disorders
- Neutrophil recruitment inhibition
- Treatment for rare diseases
Health benefits of this product:
Avacopan is a selective C5a receptor inhibitor that has been shown to have potential therapeutic benefits for several immune system disorders, including vasculitis, a rare condition that leads to inflammation of blood vessels. It is also being evaluated for its anti-inflammatory and anti-fibrotic effects in other conditions such as lupus nephritis, focal segmental glomerulosclerosis (FSGS), and certain dermatologic diseases.
Avacopan has shown promising results in early clinical trials for the treatment of vasculitis. It has the potential to selectively block the C5a receptor, which plays a role in the neutrophil recruitment and activation, and ultimately inflammation. By blocking this receptor, avacopan could reduce inflammation in patients with vasculitis and other inflammatory conditions.
The complement system is a part of the immune system that plays a role in inflammation and the control of infectious agents. One of the important components of the complement system is C5a, which binds to its receptor and promotes the recruitment and activation of neutrophils at sites of inflammation. Avacopan works by specifically inhibiting the interaction between C5a and its receptor, thus reducing the recruitment and activation of neutrophils, and reducing inflammation in tissues.
Avacopan has been shown to be well tolerated in clinical trials. However, as with any medication, some side effects may occur. Some of the known potential side effects of avacopan include diarrhea, nausea, and headaches. Patients should always consult their healthcare provider before starting any new medication.
The side effects of avacopan are generally mild and include diarrhea, nausea, and headaches, which are common with many medications. However, severe side effects may occur in some cases. Patients should always inform their healthcare provider if they experience any unusual symptoms while taking avacopan